{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:35:13Z","timestamp":1780472113095,"version":"3.54.1"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>A 38-years-old female with an aortic valve replacement presented to an outside hospital (OSH) with fevers and malaise. Blood cultures revealed VRE which was resistant to linezolid, resistant to ampicillin, non-susceptible to daptomycin (MIC of 8\u2009mcg\/mL), and exhibited susceptibility to gentamicin. The patient was therefore initiated on intravenous (IV) daptomycin 6\u2009mg\/kg q24h and gentamicin IV 1\u2009mg\/kg q8h. However, after 14\u2009days of therapy with daptomycin and gentamicin, the patient was transferred to our institution for the management of cardiogenic shock and hypoxemic respiratory failure. Given the concern for treatment failure, her antimicrobial regimen was changed to IV chloramphenicol 12.5\u2009mg\/kg every 6\u2009hours with IV daptomycin 10\u2009mg\/kg every 48\u2009hours given an estimated creatinine clearance of 30\u2009mL\/minutes. In vitro susceptibilities for chloramphenicol were performed which confirmed susceptibility. A transesophageal echocardiogram revealed a possible abscess at the left coronary cusp and aortic valve dehiscence. The patient underwent aortic valve replacement with aortic root reconstruction. The aortic valve culture grew VRE susceptible to linezolid but resistant to ampicillin and doxycycline. The patient was deemed clinically cured after 42\u2009days of combination therapy with daptomycin and chloramphenicol. After 6\u2009years of follow-up, the patient has not had a recurrent VRE infection. To our knowledge, this is the first case of endocarditis secondary to VRE that was successfully managed with the combination of daptomycin and chloramphenicol.<\/jats:p>","DOI":"10.1177\/00185787211032364","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T02:31:44Z","timestamp":1626316304000},"page":"345-348","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Combination Therapy of Chloramphenicol and Daptomycin for the Treatment of Infective Endocarditis Secondary to Multidrug Resistant\n                    <i>Enterococcus faecium<\/i>"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-1451","authenticated-orcid":false,"given":"Sunish","family":"Shah","sequence":"first","affiliation":[{"name":"Yale New Haven Hospital, CT, USA"},{"name":"University of Pittsburgh Medical Center, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna","family":"McManus","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Topal","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, CT, USA"},{"name":"Yale School of Medicine, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"bibr1-00185787211032364","unstructured":"Jarvis WR, Gaynes RP, Horan TC, et al. Semiannual Report: Aggregated Data from the National Nosocomial Infections Surveillance (NNIS) System. Centers for Disease Control and Prevention; 1996:1-27."},{"key":"bibr2-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963631"},{"key":"bibr3-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12236"},{"key":"bibr4-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl427"},{"key":"bibr5-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1086\/659152"},{"key":"bibr6-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"bibr7-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"bibr8-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.10.018"},{"key":"bibr9-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01453-17"},{"key":"bibr10-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2001.00189.x"},{"key":"bibr11-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1086\/515002"},{"key":"bibr12-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1137"},{"key":"bibr13-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1086\/340527"},{"key":"bibr14-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1086\/319986"},{"key":"bibr15-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000047962.61701.57"},{"key":"bibr16-00185787211032364","volume-title":"Performance Standards for Antimicrobial Disk Susceptibility Tests","author":"CLSI","year":"2018","edition":"13"},{"key":"bibr17-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.10.2.173"},{"key":"bibr18-00185787211032364","unstructured":"Tygacil (Tigecycline) [package insert]. Wyeth Pharmaceuticals."},{"key":"bibr19-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.236"},{"key":"bibr20-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05077-14"},{"key":"bibr21-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-06"},{"key":"bibr22-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02790-13"},{"key":"bibr23-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.4.557"},{"key":"bibr24-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0000000000000837"},{"issue":"5","key":"bibr25-00185787211032364","first-page":"605","volume":"64","author":"Britt NS","year":"2017","journal-title":"Clin Infect Dis"},{"key":"bibr26-00185787211032364","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-33-6-1459"},{"key":"bibr27-00185787211032364","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080020064025"},{"key":"bibr28-00185787211032364","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2700.150401"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211032364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787211032364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211032364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:39:36Z","timestamp":1777451976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787211032364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/00185787211032364"],"URL":"https:\/\/doi.org\/10.1177\/00185787211032364","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}